4-Chloro-1-(2,3-dihydro-1H-indol-1-yl)butan-1-one → 4-[4-(3-Chlorophenyl)piperazin-1-yl]-1-(2,3-dihydro-1H-indol-1-yl)butan-1-one

HRID 1354065

반응식

HRID 1354065 반응식
Cl.Cl.[Cl:3][C:4]1[CH:5]=[C:6]([N:10]2[CH2:15][CH2:14][NH:13][CH2:12][CH2:11]2)[CH:7]=[CH:8][CH:9]=1.Cl[CH2:17][CH2:18][CH2:19][C:20]([N:22]1[C:30]2[C:25](=[CH:26][CH:27]=[CH:28][CH:29]=2)[CH2:24][CH2:23]1)=[O:21]>>[Cl:3][C:4]1[CH:5]=[C:6]([N:10]2[CH2:15][CH2:14][N:13]([CH2:17][CH2:18][CH2:19][C:20]([N:22]3[C:30]4[C:25](=[CH:26][CH:27]=[CH:28][CH:29]=4)[CH2:24][CH2:23]3)=[O:21])[CH2:12][CH2:11]2)[CH:7]=[CH:8][CH:9]=1

참가 물질

3

반응물 2

HCID 35980624-Chloro-1-(2,3-dihydro-1H-indol-1-yl)butan-1-oneHCID 119574871-(3-Chlorophenyl)piperazine dihydrochloride

생성물 1

HCID 119528314-[4-(3-Chlorophenyl)piperazin-1-yl]-1-(2,3-dihydro-1H-indol-1-yl)butan-1-one

실험 절차

from 1-(3-chlorophenyl)piperazine, dihydrochloride and 4-chloro-1-(2,3-dihydro-1H-indol-1-yl)butan-1-one. Mp 102–107° C. 1H NMR (DMSO-d6): 1.75–1.85 (m, 2H); 2.35 (t, 2H); 2.45–2.55 (m, 6H); 3.10–3.20 (m, 6H); 4.10 (t, 2H); 6.75 (d, 1H); 6.85 (d, 1H); 6.90 (s, 1H); 6.95 (t, 1H); 7.10 (t, 1H); 7.15–7.25 (m, 2H); 8.10 (d, 1H). MS m/z: 384 (MH+), 265, 188.

출처 및 근거

ORD 기록
ord-b45953118af84d75b6dc46d9cc2efa40
출처 데이터셋
uspto-grants-2007_05
특허 번호
US07223765B2

연결된 노트

불러오는 중…